EU GMP Guide to Apply Only to Human Medicines Starting July 16, 2026, with New Regulations for Veterinary Products

Significant changes to the European Union's Good Manufacturing Practice (GMP) guide are taking effect on July 16, 2026. From this date, EudraLex Volume 4, which previously applied to both human and veterinary medicinal products, will now only apply to human medicines. New regulations will cover the GMP for veterinary APIs and products, marking a substantial shift in the regulatory framework for pharmaceutical manufacturing in the EU.

Context

The EU's Good Manufacturing Practice guide has historically governed both human and veterinary medicinal products under EudraLex Volume 4. The decision to separate these regulations reflects evolving standards and the need for tailored guidelines for different types of medicines. This change is part of a broader effort to enhance regulatory frameworks within the EU's pharmaceutical sector.

Why it matters

The upcoming changes to the EU GMP guide are significant as they will streamline regulations specifically for human medicines, potentially enhancing safety and efficacy standards. This shift may also lead to increased focus on the unique requirements of veterinary products, which could improve their manufacturing processes. Understanding these changes is crucial for stakeholders in the pharmaceutical industry, including manufacturers and regulatory bodies.

Implications

The separation of GMP guidelines may lead to improved manufacturing practices for both human and veterinary medicines, potentially benefiting public health and animal welfare. Pharmaceutical companies may need to invest in new processes and training to meet the upcoming requirements. This regulatory shift could also impact market dynamics, influencing competition and innovation within the veterinary sector.

What to watch

As the July 2026 implementation date approaches, stakeholders should monitor the development of new regulations for veterinary products. Industry responses and adaptations to the revised GMP guidelines will be critical, particularly how companies prepare for compliance. Additionally, feedback from veterinary product manufacturers may shape the final regulations.